These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32221162)

  • 21. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
    Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment.
    Yu ML; Huang CF; Yeh ML; Tsai PC; Huang CI; Hsieh MH; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL
    Clin Cancer Res; 2017 Apr; 23(7):1690-1697. PubMed ID: 27733478
    [No Abstract]   [Full Text] [Related]  

  • 24. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
    Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
    Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expert opinion on managing chronic HCV in patients with non-Hodgkin lymphoma and other extrahepatic malignancies.
    Ferri C; Feld JJ; Bondin M; Cacoub P
    Antivir Ther; 2018; 23(Suppl 2):23-33. PubMed ID: 30451149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort.
    Liu TW; Tsai PC; Huang CI; Tsai YS; Wang SC; Ko YM; Lin CC; Chen KY; Liang PC; Lin YH; Hsieh MY; Hou NJ; Huang CF; Yeh ML; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
    J Formos Med Assoc; 2018 Jan; 117(1):54-62. PubMed ID: 28389143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
    J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
    Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
    Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
    Cacoub P; Desbois AC; Comarmond C; Saadoun D
    Gut; 2018 Nov; 67(11):2025-2034. PubMed ID: 29703790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
    Allaire M; Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; DI Martino V; Sutton A; Letouzé E; Audureau E; Roudot-Thoraval F;
    Hepatology; 2018 Oct; 68(4):1245-1259. PubMed ID: 29663511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lifestyles Associated with Prognosis After Eradication of Hepatitis C Virus: A Prospective Cohort Study in Japan.
    Ohfuji S; Matsuura T; Tamori A; Kubo S; Sasaki S; Kondo K; Ito K; Fukushima W
    Dig Dis Sci; 2021 Jun; 66(6):2118-2128. PubMed ID: 32720018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
    Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan.
    Fwu CW; Chien YC; You SL; Nelson KE; Kirk GD; Kuo HS; Feinleib M; Chen CJ
    Hepatology; 2011 Apr; 53(4):1217-25. PubMed ID: 21480326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
    Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
    Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH).
    Tsai PC; Chen CY; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Ke CK; Yu ML
    Open Forum Infect Dis; 2020 Oct; 7(10):ofaa397. PubMed ID: 33376753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
    Yen YH; Lin MT; Kuo FY; Chang KC; Tsai MC; Tseng PL; Wu CK; Lin JT; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH
    Liver Int; 2018 Jun; 38(6):1064-1073. PubMed ID: 29164767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.
    Rossi C; Saeed S; Cox J; Vachon ML; Martel-Laferrière V; Walmsley SL; Cooper C; Gill MJ; Hull M; Moodie EEM; Klein MB;
    AIDS; 2018 Mar; 32(6):751-759. PubMed ID: 29369156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis.
    Bang CS; Song IH
    BMC Gastroenterol; 2017 Apr; 17(1):46. PubMed ID: 28376711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.